Overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy according to their participation (or not) in clinical trials.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jatinder Goyal, Peng Huang, Prachi Tyagi, Daniel Oh, Michael Anthony Carducci, Mario A. Eisenberger, Emmanuel S. Antonarakis
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2587196322